Myeloproliferative Neoplasms and Bone Structure

Study Overview
=================
Brief Summary
-----------------
This is a clinical study to evaluate the effect of CMPN (Chronic myeloproliferative neoplasm) to the bone. The hypothesis is that patients with CMPN have a higher fracture-rate compared to the background population. We expect to find a lower BMD using conventional DXA scan (dual energy x-ray absorptiometry), and a change in other parameters using HR-pQCT (high-resolution peripheral quantitative computerized tomography).Biochemical bone markers is measured to support the hypothesis.

Detailed Description
-----------------
This is a clinical study to evaluate the effect of CMPN to the bone. Three individual cohorts are defined; a cohort consisting of 50 patients with Polycythemia Vera (PV), a cohort consisting of 50 patients with Essential Thrombocythemia (ET), and a cohort consisting of 25 patients with Primary Myelofibrosis (PMF). Patients are recruited from the Department of Hematology, Odense University Hospital. Interventions consist of: Conventional DXA scan to measure Bone Mineral Density (BMD). Experimental HR-pQCT to assess geometry, strength and microstructure of the bone in 3 dimension. Blood-samples are collected and frozen for later analyses of Biochemical Bone Markers: 1-CTP, Ctx, ALP (alkaline phosphatase)and P1NP. The outcome is compared to healthy control individuals.

Official Title
-----------------
Myeloproliferative Neoplasms and Bone Structure

Conditions
-----------------
Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of PV (according to WHO 2008 criteria), only JAK2-pos.(Janus kinase 2) Diagnosis of ET (according to WHO 2008 criteria), only JAK2-pos. Diagnosis of PMF (according to WHO 2008 criteria)independent of JAK2-status. Exclusion Criteria: Pregnancy Bone Diseases (Mb. Pagets, Myelomatosis, MGUS (monoclonal gammopathy of undetermined significance), osteogenesis imperfecta, Prim. hyperparathyroidism, osteomalacia. Drugs (Prednisone>3 mth, anti-osteoporotic drugs, anti-estrogen drugs. Presence of any psychologic condition or language barrier, which may interfere which a complete understanding, and arise ethnical considerations.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bone Mineral Density (BMD) | Patients will undergo one DXA scan independent of time of CMPN diagnosis | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of Geometry, Strength and Micro-Structure of the bone. | Patients will undergo one HR.pQCT indepedent of the time of the diagnosis of CMPN | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CMPN, Fracture, Osteoporosis, Biochemical Bone Markers